1. Lischner MW, Alexander JF, Galambos JT. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis 1971; 16: 481-494.
2.
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769.
3.
Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981; 10: 417-441.
4.
Morgan TR. Management of alcoholic hepatitis. Gastroenterol Hepatol 2007; 3: 97-99.
5.
Hall P, Cash J. What is the real function of the liver ‘function’ tests? Ulster Med J 2012; 81: 30-36.
6.
Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20: 11684-11699.
7.
Li CP, Lee FY, Hwang SJ, et al. Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor. World J Gastroenterol 2003; 9: 2832-2835.
8.
Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: A New View of an old problem. Clin Gastroenterol Hepatol 2015; 13: 2109-2117.
9.
Iruzubieta P, Terán Á, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol 2014; 6: 901-915.
10.
Elangovan H, Chahal S, Gunton JE. Vitamin D in liver disease: Current evidence and potential directions. Biochim Biophys Acta Mol Basis Dis 2017; 1863: 907-916.
11.
Lee SM, Jun DW, Cho YK, Jang KS. Vitamin D deficiency in non-alcoholic fatty liver disease: The chicken or the egg? Clin Nutr 2017; 36: 191-197.
12.
Kucukazman M, Ata N, Dal K, et al. The association of vitamin D deficiency with non-alcoholic fatty liver disease. Clinics (Sao Paulo) 2014; 69: 542-546.
13.
Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol 2016; 29: 297-306.
14.
Testino G, Leone S, Fagoonee S. Alcoholic liver disease and vitamin D deficiency. Minerva Med 2018; 109: 341-343.
15.
Long RG, Skinner RK, Wills MR, Sherlock S. Serum-25-hydroxy-vitamin-D in untreated parenchymal and cholestatic liver disease. Lancet 1976; 2: 650-652.
16.
Savic Z, Damjanov D, Curic N, et al. Vitamin D status, bone metabolism and bone mass in patients with alcoholic liver cirrhosis. Bratisl Lek Listy 2014; 115: 573-578.
17.
Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624-2628.
18.
Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 2180-2187.
19.
Dong B, Zhou Y, Wang W, et al. Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice. Hepatology 2020; 71: 1559-1574.
20.
Stokes CS, Krawczyk M, Reichel C, et al. Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. Eur J Clin Invest 2014; 44: 176-183.
21.
Abramovitch S, Sharvit E, Weisman Y, et al. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. Am J Physiol Gastrointest Liver Physiol 2015; 308: G112-120.
22.
Kawaratani H, Moriya K, Namisaki T, et al. Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). Int J Mol Med 2017; 40: 263-270.
23.
Astakhin AV, Levitan BN, Afanas’ev SS, et al. Tumor necrosis factor-alpha and interleukin-4 in the blood sera of chronic hepatitis patients. Zh Mikrobiol Epidemiol Immunobiol 2004; 2: 46-50.
24.
Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016; 64: 955-965.
25.
Tung KH, Huang YS, Yang KC, et al. Serum interleukin-12 levels in alcoholic liver disease. J Chin Med Assoc 2010; 73: 67-71.
26.
Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
27.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.
28.
Yu Y, Venners SA, Wang B, et al. Association of central adiposity with prediabetes and decreased insulin sensitivity in rural Chinese normal-weight and overweight women. Metabolism 2010; 59: 1047-1053.
29.
Abbott Laboratories: Brochure: IA_09_23864/v1, AK2117-10 No. In.; 2010.
30.
Grunkemeier GL, Wu Y. Bootstrap resampling methods: something for nothing? Ann Thorac Surg 2004; 77: 1142-1144.
31.
Spearman Rank Correlation Coefficient. In: The Concise Encyclopedia of Statistics. edn. Springer New York, New York, NY 2008; 502-505.
32.
Li G, Wu W, Zhang X, et al. Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity. BMC Nephrol 2018; 19: 326.
33.
Zhang J, Bai C. Elevated serum interleukin-8 level as a preferable biomarker for identifying uncontrolled asthma and glucocorticosteroid responsiveness. Tanaffos 2017; 16: 260-269.
34.
Tomasiuk R, Zubrzycki IZ, Wiacek M. Age-dependent changes in fat- and water-soluble vitamins-National Health and Nutrition Examination Surveys study. Front Med 2022; 9: 907067.
35.
O’Neill CM, Lu C, Corbin KL, et al. Circulating levels of IL-1B +IL-6 cause ER stress and dysfunction in islets from prediabetic male mice. Endocrinology 2013; 154: 3077-3088.
36.
Said EA, Al-Reesi I, Al-Shizawi N, et al. Defining IL-6 levels in healthy individuals: A meta-analysis. J Med Virol 2021; 93: 3915-3924.
37.
Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) – relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 169-173.
38.
Chan WSA, Liew CF, Theng CTS, Oon HH. Serum adiponectin levels and their association with cardiometabolic risk factors in patients with psoriasis. Cureus 2020; 12: e8128.
39.
Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. Liver Res 2018; 2: 161-172.
40.
Rey I, Effendi-Ys R. Association between serum IL-6, IL-10, IL-12, and IL-23 levels and severity of liver cirrhosis. Med Arch 2021; 75: 199-203.
41.
Tomasiuk R, Zubrzycki IZ, Wiacek M. Age-dependent changes in fat- and water-soluble vitamins – NHANES study. Unpublished 2022.
42.
Putz-Bankuti C, Pilz S, Stojakovic T, et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int 2012; 32: 845-851.
43.
Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-978.
44.
El Menyawi M, Fawzy M, Al-Nahas Z, et al. Serum tumor necrosis factor alpha (TNF-α) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity. Egypt Rheumatol 2014; 36: 139-143.
45.
Mourtzikou A, Alepaki M, Stamouli M, et al. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Inmunología 2014; 33: 41-50.
46.
Naveau S, Emilie D, Balian A, et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J Hepatol 1998; 28: 778-784.
47.
Neuman MG, Maor Y, Nanau RM, et al. Alcoholic liver disease: Role of cytokines. Biomolecules 2015; 5: 2023-2034.
48.
Sheron N, Bird G, Goka J, et al. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991; 84: 449-453.
49.
Hong F, Kim WH, Tian Z, et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene 2002; 21: 32-43.
50.
Hill DB, Marsano L, Cohen D, et al. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992; 119: 547-552.
51.
Prystupa A, Kiciński P, Sak J, et al. Proinflammatory cytokines (IL-1α, IL-6) and hepatocyte growth factor in patients with alcoholic liver cirrhosis. Gastroenterol Res Pract 2015; 2015: 532615.
52.
Feng L, Qi Q, Wang P, et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res 2018; 46: 5228-5236.
53.
Huang YS, Chan CY, Wu JC, et al. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol 1996; 24: 377-384.
54.
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
55.
Laso FJ, Iglesias MC, Lopez A, et al. Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol 1998; 28: 771-777.
56.
Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014; 2014: 658913-658913.
57.
Suárez-Álvarez K, Solís-Lozano L, Leon-Cabrera S, et al. Serum IL-12 is increased in Mexican obese subjects and associated with low-grade inflammation and obesity-related parameters. Mediators Inflamm 2013; 2013: 967067.
58.
Buechler C, Schaffler A, Johann M, et al. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol 2009; 24: 558-563.
59.
Kalafateli M, Triantos C, Tsochatzis E, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol 2015; 21: 3020-3029.
60.
Stefan N, Stumvoll M. Adiponectin – its role in metabolism and beyond. Horm Metab Res 2002; 34: 469-474.
61.
Borges MD, Franca EL, Fujimori M, et al. Relationship between proinflammatory cytokines/chemokines and adipokines in serum of young adults with obesity. Endocr Metab Immune Disord Drug Targets 2018; 18: 260-267.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
